中国临床药理学杂志2024，Vol.40Issue(9)：1368-1371,4.DOI:10.13699/j.cnki.1001-6821.2024.09.027
治疗成人重症肌无力新药zilucoplan的药理作用与临床评价
Pharmacological effects and clinical evaluation of zilucoplan for generalized myasthenia gravis
程璐 1解染 1赵楠 1贾博 1赵侠1
作者信息
- 1. 北京大学第一医院药物临床试验机构,北京 100009
- 折叠
摘要
Abstract
Zilucoplan is a novel subcutaneous self-administered macrocyclic peptide inhibitor of complement component 5.It was approved by the FDA in October 2023 for the treatment of adults with generalized myasthenia gravis(gMG)who are positive for acetylcholine receptor(AChR)antibodies.This article reviews its pharmacological action,pharmacokinetics,clinical evaluation and safety.关键词
zilucoplan/补体C5抑制剂/重症肌无力/临床评价/安全性Key words
zilucoplan/inhibitor of complement component 5/generalized myasthenia gravis/clinical evaluation/safety分类
医药卫生引用本文复制引用
程璐,解染,赵楠,贾博,赵侠..治疗成人重症肌无力新药zilucoplan的药理作用与临床评价[J].中国临床药理学杂志,2024,40(9):1368-1371,4.
